Skip to main content
Lincoln Pharmaceuticals ltd. logo

Lincoln Pharmaceuticals ltd. — Investor Relations & Filings

Ticker · LINCOLN ISIN · INE405C01035 LEI · 3358004B6OBJNW8RTT10 BSE.NS Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2019-09-05 Regulatory Filings
Country IN India
Listing BSE.NS LINCOLN

About Lincoln Pharmaceuticals ltd.

https://www.lincolnpharma.com/

Lincoln Pharmaceuticals Ltd. focuses on the development, manufacturing, and marketing of a diverse range of therapeutic formulations. The organization operates advanced manufacturing facilities certified by international standards, including WHO-GMP. Its portfolio spans multiple areas such as anti-infectives, cardiovascular, gastrointestinal, respiratory, and pain management. The company is recognized for its research and development initiatives, particularly in Novel Drug Delivery Systems (NDDS). Key offerings include specialized treatments for tinnitus and a wide array of formulations in dosage forms like tablets, capsules, liquid orals, and injectables. It maintains a significant global footprint, supplying products to numerous international markets across Africa, Southeast Asia, and Latin America, supported by a robust distribution network for its extensive healthcare catalog.

Recent filings

Filing Released Lang Actions
AGM/Book Closure
Regulatory Filings
2019-09-05 English
Shareholders meeting
AGM Information Classification · 95% confidence The document is a detailed notice and accompanying materials for the 25th Annual General Meeting (AGM) of Lincoln Pharmaceuticals Limited, scheduled for September 30, 2019. It includes the AGM notice, agenda items such as adoption of financial statements, dividend declaration, and reappointment of directors, as well as detailed corporate information, board of directors, auditors, and the agenda for ordinary and special businesses. The presence of the full agenda, resolutions, and supporting reports indicates this is the actual AGM information document rather than just an announcement or proxy solicitation. The document length (15,000 characters) and content confirm it is not a brief announcement or a proxy statement but the AGM materials themselves.
2019-09-05 English
Updates
Regulatory Filings Classification · 95% confidence The document is a notice published by Lincoln Pharmaceuticals Ltd. regarding the transfer of equity shares to the Investor Education and Protection Fund (IEPF) Authority. It references compliance with SEBI regulations and the IEPF Rules, 2016, and details the process and implications of transferring shares that have unpaid or unclaimed dividends for seven consecutive years. The document is a formal notification to shareholders about this transfer and related procedures. It does not contain financial statements, audit results, management discussion, or earnings data. It is not an announcement of voting results or a proxy solicitation. The content is regulatory in nature, informing shareholders and stock exchanges about compliance actions and share transfers. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-09-04 English
Financial Result Updates
Regulatory Filings
2019-08-14 English
Outcome of Board Meeting
Regulatory Filings Classification · 95% confidence The document is very short (690 characters) and contains no substantive financial data or detailed report content. It appears to be a brief communication addressed to stock exchanges (NSE and BSE) with scrip codes mentioned, but no financial statements, management discussion, or report details are present. The presence of placeholders for images and the format suggests it might be a regulatory communication or announcement rather than a full report. Given the brevity and lack of report content, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2019-08-14 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) informing about the scheduling of a Board Meeting on August 14, 2019. The purpose of the meeting is to consider and approve the Un-Audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2019. It also mentions the closure of the trading window for insiders in compliance with SEBI regulations. The document does not contain the financial results themselves but is an announcement about the upcoming board meeting and the timing of the financial results approval. The document length is short (2387 characters) and it is clearly an intimation or notice rather than the actual financial report. Therefore, it fits the category of Regulatory Filings (RNS) as a general regulatory announcement and notification to exchanges rather than an Interim Report (IR) or Earnings Release (ER).
2019-08-03 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.